Physiologic and pathologic drug resistance in ovarian carcinoma - A hypothesis based on a clonal progression model

Lajos Pusztai, Zahid H. Siddik, Gordon Mills, Robert C. Bast

Research output: Contribution to journalReview article

18 Citations (Scopus)

Abstract

Conventional models for successful chemotherapy suggest that early- stage ovarian cancer should be more responsive to cytotoxic drugs than advanced disease, that multiple drugs will prove more efficacious than single agents and that more intensive chemotherapy will prove superior to conventional doses. The purpose of numerous clinical studies has been to test these predictions and the results often fall short of the expectations. In trials to date, adjuvant chemotherapy for high-risk, early-stage ovarian cancer has provided only a modest, equivocal increase in disease-free survival. Combination chemotherapy produces higher response rates but this has not consistently resulted in prolonged survival. Dose intensification with high-dose chemotherapy increases rate of response further, but most responses are of short duration. The objective of this review is to integrate clinical and molecular biological observations into a novel model of drug resistance. We hypothesize that drug sensitivity is an acquired characteristic of neoplastic cells, and that there are two broad cellular forms of resistance to cytotoxic drugs. 'Physiological drug resistance' is a cellular state when drug sensitivity of cancer cells is similar to that of the corresponding normal tissue. This form of drug resistance can precede the acquisition of drug sensitivity and may be predominant in the early stages of neoplastic progression. A distinct, 'pathological drug resistance' can reappear later during tumor progression or during chemotherapy as a result of increased detoxification, upregulation of repair pathways or defective apoptosis. Tumors are formed of heterogeneous cell populations and in terms of drug sensitivity three distinct cell types may be present: drug-sensitive, physiologically drug-resistant and pathologically drug-resistant. Clinical response to chemotherapy is determined by the relative contribution of these different cell populations to the total cellular mass. Depending on the predominant type of surviving population, distinct patterns of clinical failure may develop that require different treatment strategies for optimal management. For chemosensitive cells that survived insufficient chemotherapy, consolidation with further, perhaps, high-dose chemotherapy is a rational option. For pathologically drug-resistant cells, pharmacological manipulation of drug resistance, and signaling pathways in combination with chemotherapy could be exploited. For physiologically drug-resistant cells, non- chemotherapy-based, 'chemopreventive' strategies to arrest tumor progression may prove beneficial.

Original languageEnglish (US)
Pages (from-to)629-640
Number of pages12
JournalActa Oncologica
Volume37
Issue number7-8
DOIs
StatePublished - Dec 1 1998
Externally publishedYes

Fingerprint

Drug Resistance
Carcinoma
Pharmaceutical Preparations
Drug Therapy
Combination Drug Therapy
Ovarian Neoplasms
Neoplasms
Consolidation Chemotherapy
Population
Adjuvant Chemotherapy
Disease-Free Survival
Up-Regulation
Pharmacology
Apoptosis

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Physiologic and pathologic drug resistance in ovarian carcinoma - A hypothesis based on a clonal progression model. / Pusztai, Lajos; Siddik, Zahid H.; Mills, Gordon; Bast, Robert C.

In: Acta Oncologica, Vol. 37, No. 7-8, 01.12.1998, p. 629-640.

Research output: Contribution to journalReview article

Pusztai, Lajos ; Siddik, Zahid H. ; Mills, Gordon ; Bast, Robert C. / Physiologic and pathologic drug resistance in ovarian carcinoma - A hypothesis based on a clonal progression model. In: Acta Oncologica. 1998 ; Vol. 37, No. 7-8. pp. 629-640.
@article{3b33638557e0461bb8918e27ab9315a8,
title = "Physiologic and pathologic drug resistance in ovarian carcinoma - A hypothesis based on a clonal progression model",
abstract = "Conventional models for successful chemotherapy suggest that early- stage ovarian cancer should be more responsive to cytotoxic drugs than advanced disease, that multiple drugs will prove more efficacious than single agents and that more intensive chemotherapy will prove superior to conventional doses. The purpose of numerous clinical studies has been to test these predictions and the results often fall short of the expectations. In trials to date, adjuvant chemotherapy for high-risk, early-stage ovarian cancer has provided only a modest, equivocal increase in disease-free survival. Combination chemotherapy produces higher response rates but this has not consistently resulted in prolonged survival. Dose intensification with high-dose chemotherapy increases rate of response further, but most responses are of short duration. The objective of this review is to integrate clinical and molecular biological observations into a novel model of drug resistance. We hypothesize that drug sensitivity is an acquired characteristic of neoplastic cells, and that there are two broad cellular forms of resistance to cytotoxic drugs. 'Physiological drug resistance' is a cellular state when drug sensitivity of cancer cells is similar to that of the corresponding normal tissue. This form of drug resistance can precede the acquisition of drug sensitivity and may be predominant in the early stages of neoplastic progression. A distinct, 'pathological drug resistance' can reappear later during tumor progression or during chemotherapy as a result of increased detoxification, upregulation of repair pathways or defective apoptosis. Tumors are formed of heterogeneous cell populations and in terms of drug sensitivity three distinct cell types may be present: drug-sensitive, physiologically drug-resistant and pathologically drug-resistant. Clinical response to chemotherapy is determined by the relative contribution of these different cell populations to the total cellular mass. Depending on the predominant type of surviving population, distinct patterns of clinical failure may develop that require different treatment strategies for optimal management. For chemosensitive cells that survived insufficient chemotherapy, consolidation with further, perhaps, high-dose chemotherapy is a rational option. For pathologically drug-resistant cells, pharmacological manipulation of drug resistance, and signaling pathways in combination with chemotherapy could be exploited. For physiologically drug-resistant cells, non- chemotherapy-based, 'chemopreventive' strategies to arrest tumor progression may prove beneficial.",
author = "Lajos Pusztai and Siddik, {Zahid H.} and Gordon Mills and Bast, {Robert C.}",
year = "1998",
month = "12",
day = "1",
doi = "10.1080/028418698429964",
language = "English (US)",
volume = "37",
pages = "629--640",
journal = "Acta Oncologica",
issn = "0284-186X",
publisher = "Informa Healthcare",
number = "7-8",

}

TY - JOUR

T1 - Physiologic and pathologic drug resistance in ovarian carcinoma - A hypothesis based on a clonal progression model

AU - Pusztai, Lajos

AU - Siddik, Zahid H.

AU - Mills, Gordon

AU - Bast, Robert C.

PY - 1998/12/1

Y1 - 1998/12/1

N2 - Conventional models for successful chemotherapy suggest that early- stage ovarian cancer should be more responsive to cytotoxic drugs than advanced disease, that multiple drugs will prove more efficacious than single agents and that more intensive chemotherapy will prove superior to conventional doses. The purpose of numerous clinical studies has been to test these predictions and the results often fall short of the expectations. In trials to date, adjuvant chemotherapy for high-risk, early-stage ovarian cancer has provided only a modest, equivocal increase in disease-free survival. Combination chemotherapy produces higher response rates but this has not consistently resulted in prolonged survival. Dose intensification with high-dose chemotherapy increases rate of response further, but most responses are of short duration. The objective of this review is to integrate clinical and molecular biological observations into a novel model of drug resistance. We hypothesize that drug sensitivity is an acquired characteristic of neoplastic cells, and that there are two broad cellular forms of resistance to cytotoxic drugs. 'Physiological drug resistance' is a cellular state when drug sensitivity of cancer cells is similar to that of the corresponding normal tissue. This form of drug resistance can precede the acquisition of drug sensitivity and may be predominant in the early stages of neoplastic progression. A distinct, 'pathological drug resistance' can reappear later during tumor progression or during chemotherapy as a result of increased detoxification, upregulation of repair pathways or defective apoptosis. Tumors are formed of heterogeneous cell populations and in terms of drug sensitivity three distinct cell types may be present: drug-sensitive, physiologically drug-resistant and pathologically drug-resistant. Clinical response to chemotherapy is determined by the relative contribution of these different cell populations to the total cellular mass. Depending on the predominant type of surviving population, distinct patterns of clinical failure may develop that require different treatment strategies for optimal management. For chemosensitive cells that survived insufficient chemotherapy, consolidation with further, perhaps, high-dose chemotherapy is a rational option. For pathologically drug-resistant cells, pharmacological manipulation of drug resistance, and signaling pathways in combination with chemotherapy could be exploited. For physiologically drug-resistant cells, non- chemotherapy-based, 'chemopreventive' strategies to arrest tumor progression may prove beneficial.

AB - Conventional models for successful chemotherapy suggest that early- stage ovarian cancer should be more responsive to cytotoxic drugs than advanced disease, that multiple drugs will prove more efficacious than single agents and that more intensive chemotherapy will prove superior to conventional doses. The purpose of numerous clinical studies has been to test these predictions and the results often fall short of the expectations. In trials to date, adjuvant chemotherapy for high-risk, early-stage ovarian cancer has provided only a modest, equivocal increase in disease-free survival. Combination chemotherapy produces higher response rates but this has not consistently resulted in prolonged survival. Dose intensification with high-dose chemotherapy increases rate of response further, but most responses are of short duration. The objective of this review is to integrate clinical and molecular biological observations into a novel model of drug resistance. We hypothesize that drug sensitivity is an acquired characteristic of neoplastic cells, and that there are two broad cellular forms of resistance to cytotoxic drugs. 'Physiological drug resistance' is a cellular state when drug sensitivity of cancer cells is similar to that of the corresponding normal tissue. This form of drug resistance can precede the acquisition of drug sensitivity and may be predominant in the early stages of neoplastic progression. A distinct, 'pathological drug resistance' can reappear later during tumor progression or during chemotherapy as a result of increased detoxification, upregulation of repair pathways or defective apoptosis. Tumors are formed of heterogeneous cell populations and in terms of drug sensitivity three distinct cell types may be present: drug-sensitive, physiologically drug-resistant and pathologically drug-resistant. Clinical response to chemotherapy is determined by the relative contribution of these different cell populations to the total cellular mass. Depending on the predominant type of surviving population, distinct patterns of clinical failure may develop that require different treatment strategies for optimal management. For chemosensitive cells that survived insufficient chemotherapy, consolidation with further, perhaps, high-dose chemotherapy is a rational option. For pathologically drug-resistant cells, pharmacological manipulation of drug resistance, and signaling pathways in combination with chemotherapy could be exploited. For physiologically drug-resistant cells, non- chemotherapy-based, 'chemopreventive' strategies to arrest tumor progression may prove beneficial.

UR - http://www.scopus.com/inward/record.url?scp=0032414270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032414270&partnerID=8YFLogxK

U2 - 10.1080/028418698429964

DO - 10.1080/028418698429964

M3 - Review article

C2 - 10050979

AN - SCOPUS:0032414270

VL - 37

SP - 629

EP - 640

JO - Acta Oncologica

JF - Acta Oncologica

SN - 0284-186X

IS - 7-8

ER -